This study was designed to investigate antipsychotic properties of cholecystokinin-octapeptide (CCK-8) in schizophrenic patients. Subjects were 30 chronic schizophrenics with residual symptoms following stablization with antipsychotic drugs. CCK-8 (0.2jig/kg) or placebo was administered intravenously single injection with double-blind method while patients received constant dose of antipsychotic drugs. The clinical effect of CCK-8 was evaluated with BPRS which was applied to patients 2 hours before and 3 and 7 days after drug administration. Results showed no significant differences between CCK-8 group and placebo group.
서 론
연구방법
결 과
고 찰
결 론
참 고 문 헌